CN103585192A - 一种通经草提取物的制备方法及其应用 - Google Patents
一种通经草提取物的制备方法及其应用 Download PDFInfo
- Publication number
- CN103585192A CN103585192A CN201310525384.4A CN201310525384A CN103585192A CN 103585192 A CN103585192 A CN 103585192A CN 201310525384 A CN201310525384 A CN 201310525384A CN 103585192 A CN103585192 A CN 103585192A
- Authority
- CN
- China
- Prior art keywords
- gmel
- aleuritopteris argentea
- fee
- fee extract
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000688694 Cheilanthes argentea Species 0.000 title claims abstract description 212
- 239000000284 extract Substances 0.000 title claims abstract description 190
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 31
- 239000011347 resin Substances 0.000 claims abstract description 25
- 229920005989 resin Polymers 0.000 claims abstract description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 14
- 238000010262 high-speed countercurrent chromatography Methods 0.000 claims abstract description 8
- 239000002552 dosage form Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- 239000002253 acid Substances 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 19
- 239000003463 adsorbent Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 16
- LNWOKEZJIRLIDO-ZJGHDVHGSA-N (E)-5-[(1S,4aR,6S,8aR)-6-hydroxy-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)[C@@H](CCC(/C)=C/C(O)=O)C(=C)CC[C@H]21 LNWOKEZJIRLIDO-ZJGHDVHGSA-N 0.000 claims description 15
- LNWOKEZJIRLIDO-UHFFFAOYSA-N 15-Carboxylic acid-(ent-3beta,13Z)-8(17),13-Labdadien-3,15-diol Natural products CC1(C)C(O)CCC2(C)C(CCC(C)=CC(O)=O)C(=C)CCC21 LNWOKEZJIRLIDO-UHFFFAOYSA-N 0.000 claims description 15
- LTVBTVOAUQJJEV-UHFFFAOYSA-N 4-methylindeno[1,2-b]pyridin-5-one Chemical compound C12=CC=CC=C2C(=O)C2=C1N=CC=C2C LTVBTVOAUQJJEV-UHFFFAOYSA-N 0.000 claims description 15
- BZYOCVKVXZEFJW-UHFFFAOYSA-N 5,7-dihydroxy-2-(3-methoxyphenyl)-6,8-dimethyl-2,3-dihydrochromen-4-one Chemical compound COC1=CC=CC(C2OC3=C(C)C(O)=C(C)C(O)=C3C(=O)C2)=C1 BZYOCVKVXZEFJW-UHFFFAOYSA-N 0.000 claims description 15
- 241000703529 Dryopteris lacera Species 0.000 claims description 15
- UVPBNPUZWAOBQX-UHFFFAOYSA-N Sarotanoside Natural products OC1C(O)C(O)C(C)OC1OC1C(OC=2C=C3OC(CC(=O)C3=C(O)C=2)C=2C=CC=CC=2)OC(CO)C(O)C1O UVPBNPUZWAOBQX-UHFFFAOYSA-N 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 239000002244 precipitate Substances 0.000 claims description 14
- 238000010828 elution Methods 0.000 claims description 13
- 241000238631 Hexapoda Species 0.000 claims description 10
- 241001453658 Onychium japonicum Species 0.000 claims description 10
- 229930003949 flavanone Natural products 0.000 claims description 10
- 150000002208 flavanones Chemical class 0.000 claims description 10
- 235000011981 flavanones Nutrition 0.000 claims description 10
- 229930182478 glucoside Natural products 0.000 claims description 10
- 150000008131 glucosides Chemical class 0.000 claims description 10
- 229930182470 glycoside Natural products 0.000 claims description 10
- 229940088597 hormone Drugs 0.000 claims description 10
- 239000005556 hormone Substances 0.000 claims description 10
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 7
- 239000003480 eluent Substances 0.000 claims description 7
- HZQXXYJHLCSUGQ-UHFFFAOYSA-N ethyl acetate hexane methanol hydrate Chemical compound O.OC.CCCCCC.CCOC(C)=O HZQXXYJHLCSUGQ-UHFFFAOYSA-N 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 230000002879 macerating effect Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 5
- HAIHGFWQOPJMPV-UHFFFAOYSA-N (S)-5,7-Dihydroxy-6,8-dimethylflavanone Chemical compound C1C(=O)C2=C(O)C(C)=C(O)C(C)=C2OC1C1=CC=CC=C1 HAIHGFWQOPJMPV-UHFFFAOYSA-N 0.000 claims description 5
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims description 5
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 5
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 claims description 5
- 230000000274 adsorptive effect Effects 0.000 claims description 5
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 5
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 5
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 claims description 5
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 claims description 5
- 235000011797 eriodictyol Nutrition 0.000 claims description 5
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 claims description 5
- 150000002338 glycosides Chemical class 0.000 claims description 5
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 5
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 5
- 229940025878 hesperidin Drugs 0.000 claims description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 5
- 229930002697 labdane diterpene Natural products 0.000 claims description 5
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000009498 luteolin Nutrition 0.000 claims description 5
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims description 5
- 229930019673 naringin Natural products 0.000 claims description 5
- 229940052490 naringin Drugs 0.000 claims description 5
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 11
- 238000011097 chromatography purification Methods 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229940126701 oral medication Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 33
- 239000008103 glucose Substances 0.000 description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 30
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 30
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229960001052 streptozocin Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000010241 blood sampling Methods 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000023852 carbohydrate metabolic process Effects 0.000 description 5
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 3
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- -1 flavone compound Chemical class 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000010557 Lipid storage disease Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 208000029224 Thoracic injury Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000011697 diabetes animal model Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310525384.4A CN103585192B (zh) | 2013-10-31 | 2013-10-31 | 一种通经草提取物的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310525384.4A CN103585192B (zh) | 2013-10-31 | 2013-10-31 | 一种通经草提取物的制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103585192A true CN103585192A (zh) | 2014-02-19 |
CN103585192B CN103585192B (zh) | 2015-10-28 |
Family
ID=50075646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310525384.4A Expired - Fee Related CN103585192B (zh) | 2013-10-31 | 2013-10-31 | 一种通经草提取物的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103585192B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105061150A (zh) * | 2015-08-03 | 2015-11-18 | 河北科技大学 | 一种新型二萜醇、其制备方法及应用 |
CN106146582A (zh) * | 2016-07-18 | 2016-11-23 | 唐翔 | 一种采用微切助互作技术辅助提取橙皮苷的方法 |
CN108853185A (zh) * | 2018-05-12 | 2018-11-23 | 济南昊雨青田医药技术有限公司 | 一种降血糖有效部位的提取纯化技术 |
CN109851644A (zh) * | 2019-03-05 | 2019-06-07 | 河北科技大学 | 一种二萜醇苷类化合物、其制备方法及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1210715A (zh) * | 1997-09-09 | 1999-03-17 | 衡阳医学院 | 一种治疗恶性肿瘤的药物 |
CN1435181A (zh) * | 2002-01-31 | 2003-08-13 | 南华大学 | 金粉蕨素在制备治疗或预防心血管疾病药物中的应用 |
CN1615922A (zh) * | 2003-11-15 | 2005-05-18 | 胡硕泉 | 治疗再生障碍性贫血的中草药剂 |
-
2013
- 2013-10-31 CN CN201310525384.4A patent/CN103585192B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1210715A (zh) * | 1997-09-09 | 1999-03-17 | 衡阳医学院 | 一种治疗恶性肿瘤的药物 |
CN1435181A (zh) * | 2002-01-31 | 2003-08-13 | 南华大学 | 金粉蕨素在制备治疗或预防心血管疾病药物中的应用 |
CN1615922A (zh) * | 2003-11-15 | 2005-05-18 | 胡硕泉 | 治疗再生障碍性贫血的中草药剂 |
Non-Patent Citations (5)
Title |
---|
包玉敏等: ""通经草黄酮的体外抗氧化性"", 《光谱实验室》 * |
莎日娜: ""蒙药通经草的化学成分研究"", 《万方数据》 * |
赵迎春 等: ""通经草的化学成分研究"", 《中草药》 * |
赵迎春: ""通经草的化学成分与质量控制方法研究"", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
赵迎春等: ""通经草叶中粉背蕨酸的分离及含量测定"", 《沈阳药科大学学报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105061150A (zh) * | 2015-08-03 | 2015-11-18 | 河北科技大学 | 一种新型二萜醇、其制备方法及应用 |
CN106146582A (zh) * | 2016-07-18 | 2016-11-23 | 唐翔 | 一种采用微切助互作技术辅助提取橙皮苷的方法 |
CN108853185A (zh) * | 2018-05-12 | 2018-11-23 | 济南昊雨青田医药技术有限公司 | 一种降血糖有效部位的提取纯化技术 |
CN109851644A (zh) * | 2019-03-05 | 2019-06-07 | 河北科技大学 | 一种二萜醇苷类化合物、其制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103585192B (zh) | 2015-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102274244B (zh) | 一种肉桂多酚提取物、其制备方法及其用途 | |
CN102885937B (zh) | 酸浆有效部位群的制备方法及其应用 | |
CN103585192B (zh) | 一种通经草提取物的制备方法及其应用 | |
CN103156869A (zh) | 从桑属植物提取的桑根酮c、桑根酮d及组合物的医药新用途 | |
CN102100758B (zh) | 一种用于止痛消肿的青鹏凝胶剂及其制备方法 | |
CN103349671A (zh) | 一种白藜芦醇螺旋藻组合物及其制剂和制法 | |
CN101978982B (zh) | 竹节参或其提取物在制备抗痛风和修复高尿酸性肾损伤药物中应用 | |
CN113730464A (zh) | 香连丸及其提取物、药物组合物与香连丸产物的新用途 | |
CN101167781A (zh) | 口服降血糖红薯叶单方中药及其制备方法 | |
CN101167863A (zh) | 一种治疗糖尿病肾病的中成药及其制备方法 | |
CN106214787B (zh) | 一种治疗糖尿病的中药组合物及其制备方法与用途 | |
CN103585226B (zh) | 一种毛莲菜提取物的制备方法及其应用 | |
CN103432420B (zh) | 一种治疗糖尿病的中药组合物及其制备方法和检测方法 | |
CN109528782A (zh) | 银杏叶提取物作为增效剂在制备对睡眠障碍疾病具有治疗或保健的药物的应用 | |
CN101904894B (zh) | 独一味总苷在制备药物中的用途 | |
CN101816719A (zh) | 桃花或桃叶总黄酮及它们在制备降血糖血脂、预防和/或治疗糖尿病及并发症药物或保健品中的用途 | |
CN107778340A (zh) | (20S,24R)‑20,24‑环氧达玛烷‑3β,12β,25‑三醇及其应用 | |
CN102824423B (zh) | 一种含白芍总苷和牛蒡苷的药物组合物及应用 | |
CN102578579B (zh) | 一种具有调节血糖血脂的保健食品及其制备方法 | |
CN108853130B (zh) | 一种降血糖药物组合物及其制备方法 | |
CN107349362B (zh) | 一种用于治疗糖尿病视网膜病变的药物组合物 | |
CN101647855B (zh) | 一种治疗糖尿病神经病变的中药制剂及其制备方法 | |
CN101249129B (zh) | 一种治疗糖尿病的中药提取物组合物及其医药用途 | |
CN100355440C (zh) | 治疗ⅱ型糖尿病、降低血糖的中药复方制剂及其制备方法 | |
CN101185662A (zh) | 从肾蕨中制备的用于治疗糖尿病新药的方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: WANG SHENGLI Effective date: 20150910 Owner name: YU LI Free format text: FORMER OWNER: JINAN XINGYI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20150910 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Yu Li Inventor after: Wang Shengli Inventor before: Kong Qianqian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: KONG QIANQIAN TO: YU LI WANG SHENGLI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150910 Address after: 262299 No. 2, building 2, building 12, 101 Renmin East Road, Zhucheng City, Shandong, Weifang Applicant after: Yu Li Applicant after: Wang Shengli Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Applicant before: Jinan Xingyi Medical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Yifang Inventor after: Fu Hongjuan Inventor before: Yu Li Inventor before: Wang Shengli |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170901 Address after: 262700, Shandong, Weifang Province, Shouguang Town, No. 201, Paul Road Co-patentee after: Li Guiyun Patentee after: Chen Yifang Address before: 262299 No. 2, building 2, building 12, 101 Renmin East Road, Zhucheng City, Shandong, Weifang Co-patentee before: Wang Shengli Patentee before: Yu Li |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Shan Inventor after: Li Xiaomin Inventor after: Wang Sen Inventor before: Chen Yifang Inventor before: Fu Hongjuan |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171117 Address after: 260000 Shandong street health city of Weifang province Shouguang City, No. 47 Co-patentee after: Zhang Miaofen Patentee after: Wang Shan Address before: 262700, Shandong, Weifang Province, Shouguang Town, No. 201, Paul Road Co-patentee before: Li Guiyun Patentee before: Chen Yifang |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151028 Termination date: 20171031 |